DISCLAIMER:  Any unofficial case summaries below are prepared by the clerk's office
                        as a courtesy to the reader. They are not part of the opinion of the court.

142592P.pdf   07/02/2015  Lori Anderson  v.  K-V Pharmaceutical Company
   U.S. Court of Appeals Case No:  14-2592
   U.S. District Court for the Eastern District of Missouri - St. Louis   
   [PUBLISHED] [Shepherd, Author, with Murphy, Circuit Judge, and Harpool, 
   District Judge] 
   Civil case - Securities Fraud. In action alleging K-V and three of its 
   officers made materially false or misleading statements or omissions 
   related to the product launch of the drug Makena, the district court did 
   not err in finding defendants' statements about FDA exclusivity were 
   protected by the safe-harbor provisions of the Private Securities 
   Litigation Reform Act of 1995, 15 U.S.C. Sec. 78u-4(b) as forward-looking 
   statements accompanied by meaningful cautionary language; the district 
   court did not abuse its discretion by denying plaintiffs' motion for 
   reconsideration of the scope of leave to amend the complaint.